As the CEO of Cabaletta Bio, Catherine Bollard has been involved in insider trading activities within the company. Her trades reflect a gradual ramp-up in activity, with the value of her trades increasing consistently over time. She started in 2022...

As the CEO of Cabaletta Bio, Catherine Bollard has been involved in insider trading activities within the company. Her trades reflect a gradual ramp-up in activity, with the value of her trades increasing consistently over time. She started in 2022 with small trades of just a few thousand dollars, like $1.63K in October and gradually moved into larger trades, reaching $19.56K by December 2023. Throughout early 2024, her trading peaked at $23.20K in February before tapering off slightly. This pattern not only highlights her engagement with the company's stock but also reflects a strategic approach to trading as the company progresses. Her holdings and trading activity indicate a strong belief in Cabaletta’s growth potential in biopharma, particularly in further developing therapies that can transform patient care.